123 related articles for article (PubMed ID: 38072300)
1. Performance of SHOX2 and RASSF1A methylation assay in supernatants and matched cell pellets for the diagnosis of malignant pleural effusion.
Zhang N; Li Y; Zhang H; Dong Y; Zhang C; Du W; Long C; Xing X; Li K; Liu Z; Chen X; Zhang L; Xu F; Fu Y; Tan J; She B; Che N
Clin Chim Acta; 2024 Jan; 553():117699. PubMed ID: 38072300
[TBL] [Abstract][Full Text] [Related]
2. Combined Methylation of
Zhong Q; Wang Y; Liang C; Wei F; She B
Discov Med; 2023 Oct; 35(178):845-852. PubMed ID: 37811622
[TBL] [Abstract][Full Text] [Related]
3. DNA Methylation Analysis of the
Zhang N; Liu Z; Li K; Xing X; Long C; Liu F; She B; Che N
J Oncol; 2023; 2023():5888844. PubMed ID: 36691467
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of SHOX2, RASSF1A gene methylation combined with CEA level detection in malignant pleural effusion.
Chen S; Huang K; Zou L; Chen L; Hu P
BMC Pulm Med; 2023 May; 23(1):160. PubMed ID: 37158875
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions.
Dietrich D; Jung M; Puetzer S; Leisse A; Holmes EE; Meller S; Uhl B; Schatz P; Ivascu C; Kristiansen G
PLoS One; 2013; 8(12):e84225. PubMed ID: 24386354
[TBL] [Abstract][Full Text] [Related]
6. Cell-free DNA methylation analysis as a marker of malignancy in pleural fluid.
Bixby B; Vrba L; Lenka J; Oshiro MM; Watts GS; Hughes T; Erickson H; Chopra M; Knepler JL; Knox KS; Jarnagin L; Alalawi R; Kala M; Bernert R; Routh J; Roe DJ; Garland LL; Futscher BW; Nelson MA
Sci Rep; 2024 Feb; 14(1):2939. PubMed ID: 38316884
[TBL] [Abstract][Full Text] [Related]
7. A detection panel of novel methylated DNA markers for malignant pleural effusion.
Liang C; Liu N; Zhang Q; Deng M; Ma J; Lu J; Yin Y; Wang J; Miao Y; She B; Li Q; Hou G
Front Oncol; 2022; 12():967079. PubMed ID: 36176402
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study.
Fan X; Liu Y; Liang Z; Wang S; Yang J; Wu A
Pathol Oncol Res; 2022; 28():1610280. PubMed ID: 35515016
[No Abstract] [Full Text] [Related]
9. Assessment of a panel of miRNAs in serum and pleural fluid for the differential diagnosis of malignant and benign pleural effusion.
Zhu LR; Yuan RX; Xia XB; Wang Y; Zhu YM; Fi L; Li J
Cancer Biomark; 2022; 33(1):71-82. PubMed ID: 34366325
[TBL] [Abstract][Full Text] [Related]
10. SHOX2 DNA methylation is a tumour marker in pleural effusions.
Ilse P; Biesterfeld S; Pomjanski N; Fink C; Schramm M
Cancer Genomics Proteomics; 2013; 10(5):217-23. PubMed ID: 24136974
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of RASSF1A and SHOX2 methylation combined with EGFR mutations for differentiation between small pulmonary nodules.
Ji XY; Li H; Chen HH; Lin J
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8557-8571. PubMed ID: 37097393
[TBL] [Abstract][Full Text] [Related]
12. [The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].
Wei F; Wei Y; Li LF; Li GL; Wang GJ
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):524-527. PubMed ID: 28728299
[No Abstract] [Full Text] [Related]
13. Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis.
Ilse P; Biesterfeld S; Pomjanski N; Wrobel C; Schramm M
Cancer Genomics Proteomics; 2014; 11(5):251-8. PubMed ID: 25331797
[TBL] [Abstract][Full Text] [Related]
14. DNA Methylation Analysis of the SHOX2 and RASSF1A Panel in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis.
Zhang C; Yu W; Wang L; Zhao M; Guo Q; Lv S; Hu X; Lou J
J Cancer; 2017; 8(17):3585-3591. PubMed ID: 29151944
[No Abstract] [Full Text] [Related]
15. Cell-Free DNA Methylation Analysis as a Marker of Malignancy in Pleural Fluid.
Bixby B; Vrba L; Lenka J; Oshiro M; Watts GS; Hughes T; Erickson H; Chopra M; Knepler JL; Knox KS; Jarnagin L; Alalawi R; Kala M; Bernert R; Routh J; Roe DJ; Garland LL; Futscher BW; Nelson MA
Res Sq; 2023 Oct; ():. PubMed ID: 37886511
[TBL] [Abstract][Full Text] [Related]
16. Performance Evaluation of
Shi J; Chen X; Zhang L; Fang X; Liu Y; Zhu X; Zhang H; Fan L; Gu J; Zhang S; She B; Han H; Yi X
Front Oncol; 2020; 10():565780. PubMed ID: 33425721
[TBL] [Abstract][Full Text] [Related]
17. The Diagnostic Potential of
Gao H; Yang J; He L; Wang W; Liu Y; Hu Y; Ge M; Ding J; Ye Q
Front Oncol; 2022; 12():849024. PubMed ID: 35837113
[TBL] [Abstract][Full Text] [Related]
18. Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer.
Li N; Zeng Y; Huang J
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1379-1393. PubMed ID: 32266538
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the comprehensive diagnosis efficiency of lung cancer, including measurement of SHOX2 and RASSF1A gene methylation.
Liu J; Bian T; She B; Liu L; Sun H; Zhang Q; Zhu J; Zhang J; Liu Y
BMC Cancer; 2024 Mar; 24(1):282. PubMed ID: 38429660
[TBL] [Abstract][Full Text] [Related]
20. Label-Free Quantitative Proteomics Identifies Novel Biomarkers for Distinguishing Tuberculosis Pleural Effusion from Malignant Pleural Effusion.
Pan L; Zhang X; Jia H; Huang M; Liu F; Wang J; Du B; Wei R; Sun Q; Xing A; Li Q; Zhang Z
Proteomics Clin Appl; 2020 Jan; 14(1):e1900001. PubMed ID: 31715074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
